Is BMS/AstraZeneca's Dapagliflozin More Than Just Another Oral Diabetes Drug?
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.
You may also be interested in...
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.
BMS Buys Into Promising Neuropathic Pain Market Via Allergan Deal
New compound could one day help Bristol tap into a growing area of unmet need in diabetes.
BMS Buys Into Promising Neuropathic Pain Market Via Allergan Deal
New compound could one day help Bristol tap into a growing area of unmet need in diabetes.